\r\nMaterials and Methods: This retrospective cohort study included 113 eyes of 113 patients who underwent pars plana vitrectomy with silicone oil tamponade for primary RRD between October 2020 and December 2024. Patients were grouped as Biotech 1000 cSt (n=42), Biotech 5000 cSt (n=27), and Teknotek 5000 cSt (n=44). Primary outcomes were final anatomical success and best-corrected visual acuity (BCVA) at 6 months. Multivariable logistic regression adjusted for proliferative vitreoretinopathy (PVR), intraoperative ILM peeling, and tamponade duration.

\r\nResults: Final anatomical success rates were 73.8%, 92.0%, and 83.7%, respectively, with no significant between-group difference (p=0.161). Six-month BCVA and BCVA change were comparable (p=0.457 and p=0.612), as were postoperative complication rates (p=0.177). ILM peeling was independently associated with lower anatomical success (OR: 0.08, 95% CI: 0.01–0.71, p=0.024). Teknotek 5000 cSt was associated with higher odds of anatomical success than Biotech 1000 cSt (OR: 14.65, 95% CI: 1.20–178.95, p=0.035).

\r\nConclusion: Standard 1000 cSt and 5000 cSt silicone oils demonstrated comparable functional outcomes and complication profiles in primary RRD surgery. The subgroup association favoring one 5000 cSt formulation should be interpreted cautiously in light of case complexity, baseline disease severity, and manufacturer-related differences. Keywords : rhegmatogenous retinal detachment; silicone oil; tamponade; vitrectomy; anatomical success